<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30229259</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1364-548X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>54</Volume>                    <Issue>83</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>16</Day>                    </PubDate>                </JournalIssue>                <Title>Chemical communications (Cambridge, England)</Title>                <ISOAbbreviation>Chem. Commun. (Camb.)</ISOAbbreviation>            </Journal>            <ArticleTitle>Towards rational design of RAD51-targeting prodrugs: platinum<sup>IV</sup>-artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells.</ArticleTitle>            <Pagination>                <MedlinePgn>11717-11720</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1039/c8cc06576d</ELocationID>            <Abstract>                <AbstractText>Two PtIV-artesunate anticancer prodrugs that target RAD51, a crucial protein in homologous recombination mediating the sensitivity of cancer cells to DNA-damaging agents, were designed; their cytotoxicities against BRCA-proficient ovarian and breast cancer cells are significantly higher than those of cisplatin.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Shuren</ForeName>                    <Initials>S</Initials>                    <Suffix/>                    <AffiliationInfo>                        <Affiliation>State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, P. R. China. zguo@nju.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuan</LastName>                    <ForeName>Hao</ForeName>                    <Initials>H</Initials>                    <Suffix/>                </Author>                <Author ValidYN="Y">                    <LastName>Guo</LastName>                    <ForeName>Yan</ForeName>                    <Initials>Y</Initials>                    <Suffix/>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Kun</ForeName>                    <Initials>K</Initials>                    <Suffix/>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Xiaoyong</ForeName>                    <Initials>X</Initials>                    <Suffix/>                </Author>                <Author ValidYN="Y">                    <LastName>Guo</LastName>                    <ForeName>Zijian</ForeName>                    <Initials>Z</Initials>                    <Suffix/>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Chem Commun (Camb)</MedlineTA>            <NlmUniqueID>9610838</NlmUniqueID>            <ISSNLinking>1359-7345</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>60W3249T9M</RegistryNumber>                <NameOfSubstance UI="C039726">artesunate</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.7.-</RegistryNumber>                <NameOfSubstance UI="D051135">Rad51 Recombinase</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D037621" MajorTopicYN="N">Artemisinins</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011355" MajorTopicYN="N">Prodrugs</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051135" MajorTopicYN="N">Rad51 Recombinase</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30229259</ArticleId>            <ArticleId IdType="doi">10.1039/c8cc06576d</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>